MECFA Blog

News & Articles

Researchers Develop Promising Antibiotic Molecule for Drug-resistant Lung Infections

A man-made antibiotic able to fight drug-resistant bacteria in the lungs with minimal toxicity to a person’s cells may be a promising approach to eliminate lung infections, such as those caused by resistant Pseudomonas aeruginosa, that trouble people with cystic fibrosis (CF), a study suggests. The antibiotic molecule was tested in the lab and in mice with lung infections, where it effectively cleared the resistant bacteria without notable side effects. The findings warrant its clinical testing as an aerosol against multi-drug resistant bacteria in the lungs, researchers noted. The study, “Enhanced therapeutic index of an antimicrobial peptide in mice by increasing safety and activity agains

Rare Diseases Clinical Research Network Opens Online Survey on COVID-19

The Rare Diseases Clinical Research Network (RDCRN) has opened an online survey to better understand how the COVID-19 outbreak is affecting people with rare diseases, their families, and caregivers. Survey questions cover a patient’s physical and mental health, supply of treatments, and access to healthcare, among other disease-related issues and those brought by the pandemic. Developed and led by the RDCRN Data Management and Coordinating Center at Cincinnati Children’s Hospital Medical Center, the research survey is one of the first nationwide efforts to measure how this public health crisis is challenging the 30 million people in the U.S. estimated to have one of about 7,000 known rare di

Lung CT Scans May Help Predict Mortality Risk of IPF Patients

Lung evaluations via a CT scan might help predict the mortality risk in idiopathic pulmonary fibrosis (IPF) patients more accurately than the decline in forced vital capacity, a study shows. The study, “Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome,” was published in the journal Thorax. Anti-fibrotic treatments, aimed at preventing lung scarring, can help slow the lung function decline of IPF patients. Forced vital capacity (FVC), a test that evaluates the amount of air forcefully exhaled after taking a deep breath, is commonly used to monitor lung function in IPF. Since the introduction of anti-fibrotic medications, fewer I

AzurRx BioPharma Will Conduct Phase 2b Trial of MS1819 at TDN Clinical Sites

AzurRx BioPharma has been authorized to conduct its Phase 2b OPTION 2 clinical trial evaluating MS1819, its investigative therapy for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF), at sites that are part of the Therapeutics Development Network (TDN). TDN is the largest network of CF clinical trials in the world. Supported by the Cystic Fibrosis Foundation, the TDN allows access to 91 certified U.S. care centers that specialize in CF research and facilitate patient recruitment and implementation of clinical trials. TDN’s approval comes on the heels of an authorization by an Institutional Review Board (IRB). “We are very pleased to receive the continued support o

International Trial Begins To Test Nitric Oxide As COVID-19 Treatment

A new, international clinical trial is underway that assesses inhaled nitric oxide as a treatment for patients with mild to moderate cases of COVID-19. To date, there are no targeted therapeutic treatments for COVID-19 and there are no proven interventions to prevent progression of the disease. This clinical trial in particular will monitor patients with mild to moderate cases of COVID-19 to see how they respond to inhaled nitric oxide as a treatment. Preventing disease progression in spontaneously breathing patients with mild to moderate disease could help to reduce the number of severe cases and deaths, which in turn lessens demand on healthcare resources such a critical care physicians an

Coronavirus Update: New COVID-19 Antibiotic, WLBU2, Has Been Developed That Could Fight Lung Infecti

According to a report from The Dailymail, a new COVID-19 antibiotic has been developed that could potentially fight lung infections, such as ventilator-associated pneumonia, in patients who have contracted the novel coronavirus. (Photo : Volodymyr Hryshchenko on Unsplash) A New Antibiotic Called WLBU2 Is Developed; Experts Say It Could Fight Ventilator-Associated Lung Infections The new antibiotic, called WLBU2, was developed by medical experts to fight "superbug" lung infections. According to the report, a study revealed that the drug could combat severe lung infections in mice as well as in human cells. The study showed that the new medication could help those who suffer from cystic fibros

COVID-19 Outcomes in CF Patients Similar to General Public, Study Suggests

People with cystic fibrosis (CF) infected with the new coronavirus appear to have better outcomes than initially anticipated, with their COVID-19 disease following a course similar to that of the general population, an international study suggests. This research also points to a lower incidence of coronavirus infections in this patient group compared to the public-at-large, possibly due to a lifelong adherence to social distancing and other measures that mitigate an infection risk. The study, “A Multinational Report to Characterise SARS-CoV-2 Infection in People with Cystic Fibrosis,” was published in the Journal of Cystic Fibrosis. CF patients are believed to be highly vulnerable to SARS-Co

A 1st: US study finds Gilead drug works against coronavirus

FILE - In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. On Wednesday, April 29, 2020, the company says its experimental antiviral drug has proved effective against the new coronavirus in a major U.S. government study that put it to a strict test. (Gilead Sciences via AP) UNDATED (AP) - For the first time, a major study has found that an experimental drug works against the new coronavirus, and U.S. government officials said Wednesday that they would work to make it available to appropriate patients as quickly as possible. In a study of 1,063 patients sick enough to be

AzurRx BioPharma Receives Approval to Conduct its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cysti

On track to initiate the OPTION 2 trial by the end of Q2 2020 OPTION 2 trial to compare efficacy of standard of care to 2.2 and 4.4 gram doses of MS1819 in enteric capsules Trial completion and top-line data expected in Q1 2021 NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the Company received approval to conduct of its Phase 2 OPTION 2 clinical trial to investigate MS1819 in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI) in Therapeutics Development Network (TDN) clinic

International Study Reports COVID-19 Outcomes in People With Cystic Fibrosis

Today the Cystic Fibrosis Foundation announced data from a collaborative, international effort to understand the impact of COVID-19 on people with cystic fibrosis, a genetic disease that impacts the lungs and other organs. The manuscript, published in the Journal of Cystic Fibrosis, reports on 40 people with CF across eight countries and represents the most detailed information to date on how COVID-19 impacts this high-risk population. The publication suggests that people with CF may have a lower incidence of COVID-19 than the general public, potentially due to the CF community’s strict adherence to physical distancing and other infection control measures. The rate of infection for people wi

Featured Posts
Recent Posts
Archive
Search By Tags

Support Zahra's run for Palestine CF patients.

  • Facebook Clean
  • Twitter Clean
  • Instagram - Grey Circle
  • YouTube - Grey Circle
  • LinkedIn Clean